Radiopharmaceutical imaging developer Piramal Imaging and partner Ci-Co Healthcare have received marketing approval in South Korea for Piramal's Neuraceq radiotracer.
The Ministry of Food and Drug Safety (MFDS) and National Evidence-Based Healthcare Collaborating Agency (NECA) approvals follow others from the New Health Technology Assessment (nHTA) and Korean Dementia Association (KDA) earlier this year, the two companies said.
Neuraceq is a PET imaging diagnostic radiotracer that can identify beta-amyloid plaques in the brain, which are a known biomarker for Alzheimer's disease. The agent has been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
